TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of OCD~* A minimum score of 16 on the Yale Brown Obsessive-Compulsive Scale (YBOCS) at both the screening and baseline visits~Exclusion Criteria:~* Lifetime history of psychosis or cognitive dysfunction due to a general medical condition or substance use~* A primary diagnosis of another Axis I psychiatric disorder~* Alcohol or other substance abuse or dependence within the last 6 months~* Unstable medical condition~* Clinically significant laboratory abnormality~* Failure of a previous 10-week trial of citalopram of at least 40 mg/day or escitalopram 20 mg/day~* Active suicidality~* History of violent behavior in the past year or current risk of serious violence~* A history of sensitivity to citalopram or escitalopram~* Use of other investigational drugs within 30 days of baseline or other psychotropic drugs or herbs within 14 days of baseline (28 days for fluoxetine)~* Need for concurrent psychotherapeutic intervention~* Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label Escitalopram 10-20 mg/daily (Type: EXPERIMENTAL): Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
- Randomizationn Placebo 10-20 mg daily (Type: PLACEBO_COMPARATOR): Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
- Randomization Escitalopram 10-20 mg/daily (Type: ACTIVE_COMPARATOR): Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects at the end of pregnancy ( 37-42 w ) at low risk of PPH Mean by low-risk of PPH subjects without any of the following risk factors : hypertension/preeclampsia, placental abruption during pregnancy , placenta previa , tocolysis two hours before delivery, multiple pregnancy , previous PPH, obesity ( BMI \> 35 ), anemia (Hb \< 7 g/dL), elective caesarean section , induction of labor, retention of placental material , polyhydramnios , fever during labor, use of high doses of heparin low molecular weight.~* Subjects full capacity and the willingness to give written informed consent .~Exclusion Criteria:~* Subjects with preterm pregnancy (\<37 weeks ) or with prolonged pregnancy ( \> 42 weeks )~* Subjects at the end of pregnancy ( 37 weeks - 42 weeks ) with the following risk factors for PPH (Tab1.Protocol Study, vers.2.0 of 07/05/2016)~* multiple pregnancy~* History of thromboembolic disease or high incidence of thromboembolic events in family history ( patients at high risk of thrombophilia )~* Patients with Long - QT syndrome or who are taking drugs that cause QT prolongation~* Intrauterine fetal Death~* Epilepsy~* Autoimmune disease Tab1 medical history :~* Placental abruption during pregnancy~* Placenta previa~* Hypertension / preeclampsia~* Previous PPH~* Polyhydramnios~* Obesity ( BMI \> 35 )~* Anemia ( \< 7 g / dL )

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- arm A (TXA) (Type: EXPERIMENTAL): 2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
- arm B (OXY) (Type: ACTIVE_COMPARATOR): 2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men aged 18-70~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder by diagnostic interview and chart review~* Smoke at least 10 cigarettes per day~* Clinically stable, on a stable dose of antipsychotic (schizophrenia) or mood stabilizer (bipolar) medication for at least 1 month~* No current active suicidal ideation~* Expired air carbon monoxide (CO) concentration \>9 ppm~* Willing to take study medications and set a quit date within 2-3 weeks of beginning treatment and be willing to participate in the relapse prevention and follow-up portions of the study~* Women of childbearing potential must have a negative urine pregnancy test at baseline and agree to use an approved form of contraception during the study.~Exclusion Criteria:~* DSM-IV diagnosis of dementia, neurodegenerative disease, or other organic mental disorder~* Substance use disorder other than nicotine or caffeine in the last 6 months~* Major depressive disorder within the last 6 months~* Serious unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease such that hospitalization for treatment of that illness is likely within the next 2 months~* Life-threatening arrhythmia or cerebro-vascular event within 6 months, cardiovascular event within 2 months or uncontrolled hypertension~* History of multiple head injuries with neurological sequelae, a single severe head injury with lasting neurological sequelae, or current CNS tumor~* Liver function tests elevated over twice normal~* Renal insufficiency with estimated creatinine clearance \<40 ml/min~* Plan to continue use of tobacco products othe than cigarettes (e.g., cigar, pipe)~* Use of an investigational medication or device in the past 30 days~* Current suicidal or homicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Randomized Phase: Varenicline (Type: ACTIVE_COMPARATOR): Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
- Randomized Phase: Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are females at least 18 years of age in good general health who are not menopausal.~* Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:~* Off-white (milky or gray), thin, homogeneous vaginal discharge~* Vaginal pH ≥ 4.7~* Presence of clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount~* A positive 10% KOH Whiff test.~* Have a Gram stain slide Nugent score ≥ 4 at the Baseline visit (Day 1)~Exclusion Criteria:~* Are pregnant, lactating, or planning to become pregnant during the study.~* Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex.~* Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline visit (Day 1).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYM-1219 Low Dose (Type: EXPERIMENTAL): Administered orally
- SYM-1219 High Dose (Type: EXPERIMENTAL): Administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and 29.9 kg/m², inclusive.~Exclusion Criteria:~* history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus), psychiatric or significant allergic disease excluding mild asymptomatic allergies.~* history of and/or current cardiac disease~* previously received any monoclonal antibody or fusion protein.~* history of cancer including lymphoma, leukaemia and skin cancer.~* Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) between Screening and the End of Study visit.~* intake medication with a half-life \> 24 h within 1 month or 10 half-lives of the medication prior to the administration of investigational product.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB3 (Type: EXPERIMENTAL): SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
- EU sourced Herceptin® (Type: ACTIVE_COMPARATOR): EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
- US sourced Herceptin® (Type: ACTIVE_COMPARATOR): US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pipeline for Uncoilable or Failed Aneurysms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 to 75 years, inclusive~* Patient has a single target IA in the anterior or posterior circulation that:~  a) Is located in the following regions of the internal carotid artery: i. Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments) ii. Cavernous iii. Petrous~  b) Has a neck \>4 mm or no discernible neck AND a size (maximum fundus diameter) \>10 mm~  c) Has a parent vessel with diameter 2.5 - 5.0 mm distal/proximal to the target IA~* Subject has provided written informed consent using the Institutional Review Board (IRB)-approved consent form~* Subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements~Exclusion Criteria:~* More than one IA requires treatment in the next 6 months~* Subarachnoid hemorrhage from target IA in the past 60 days~* Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)~* Irreversible bleeding disorder~* Platelet count \< 100 x 103 cells/mm3 or known platelet dysfunction~* Inability to tolerate, documented evidence of adverse reaction or contraindication to study medications~* Stent in place at the target IA~* Contraindication to CT scan or MRI~* Allergy to contrast used in angiography that cannot be medically controlled~* Known severe allergy to platinum or cobalt/chromium alloys~* Relative contraindication to angiography (e.g., serum creatinine \> 2.5 mg/dL)~* Woman of child-bearing potential who cannot provide a negative pregnancy test~* Evidence of active infection at the time of treatment~* Other conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)~* Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments to 180 days~* Extracranial stenosis greater than 50% in the carotid artery for anterior circulation aneurysms~* Intracranial stenosis greater than 50% in the treated vessel

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pipeline (Type: EXPERIMENTAL): Placement of Pipeline Embolization Device in the parent artery at the aneurysm location

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Vagus Nerve Stimulation (tVNS) and Robotic Training to Improve Arm Function After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals between 18 and 85 years of age~* First single focal unilateral supratentorial ischemic stroke with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior~* Cognitive function sufficient to understand the experiments and follow instructions (per interview with Speech Pathologist or PI)~* Fugl-Meyer assessment 12 to 44 out of 66 (neither hemiplegic nor fully recovered motor function in the muscles of the shoulder, elbow, and wrist).~Exclusion Criteria:~* Botox treatment within 3 months of enrollment~* Fixed contraction deformity in the affected limb~* Complete and total flaccid paralysis of all shoulder and elbow motor performance~* Prior injury to the vagus nerve~* Severe dysphagia~* Introduction of any new rehabilitation interventions during study~* Individuals with scar tissue, broken skin, or irremovable metal piercings that may interfere with the stimulation or the stimulation device~* Highly conductive metal in any part of the body, including metal injury to the eye; this will be reviewed on a case by case basis for PI to make a determination~* Pregnant or plan on becoming pregnant or breastfeeding during the study period~* Significant arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, sick sinus syndrome, and A-V blocks (enrollment to be determined by PI review)~* Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system; Loop recorders will be reviewed on a case by case basis by PI and the treating Cardiologist to make a determination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- active tVNS + robotic arm therapy (Type: EXPERIMENTAL): Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting \~60 minutes, 3x per week for 3 weeks.
- sham tVNS + robotic arm therapy (Type: SHAM_COMPARATOR): Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting \~60 minutes, 3x per week for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Contraceptives and Body Mass Index

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-35~* BMI \> 30kg/m2~* Proof of a normal breast and pelvic exam within last 9 months~* Self reported normal menstrual periods (24-35 days)~* Good general health~* In the investigator's opinion, are subject's veins suitable the repeat blood draws dictated by study protocol~* Single progesterone level during screening visit ≥ 3ng/mL~* Hematocrit ≥ 36%~Exclusion Criteria:~* Contradictions to COCs (history of deep vein thrombosis,myocardial infection, uncontrolled hypertension, pulmonary embolus, diabetes with vascular changes, stroke, migraines with neurologic changes, breast cancer, impaired liver function, uncontrolled thyroid disease, hypersensitivity or allergy to birth control)~* Smoker (must smoke 0 cigarettes)~* Actively seeking/involved in a weight loss program~* Currently pregnant/seeking pregnancy in the next 6 months~* Currently breast-feeding~* Past or current diagnosis of polycystic ovarian disease~* Recent use of birth control (Depot medroxyprogesterone: 6 months, Progestin implants: 6 months, Oral contraceptives, patch or ring: 2 months, Hormone impregnated IUD: 6 months)~* Currently taking medication that interferes with COC's (Rifampin, Carbamazepine, St. John's Wort)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- All participants (Type: OTHER): A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
- Aviane and Portia (Type: ACTIVE_COMPARATOR): A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
- Aviane & Aviane (Type: ACTIVE_COMPARATOR): A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed glioblastoma multiforme by biopsy or surgical resection Grade IV disease Initial diagnosis no greater than 6 weeks prior to study~PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST or ALT less than 2.5 times ULN Alkaline phosphatase less than 2.5 times ULN No chronic hepatitis B or C Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known HIV infection No medical condition that would interfere with oral medication intake (e.g., frequent vomiting or partial bowel obstruction) No other prior or concurrent malignancy except surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer No serious medical, psychological, familial, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa No concurrent biologic therapy No concurrent immunotherapy Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: At least 14 days of prior corticosteroids at a stable dose required Concurrent corticosteroids allowed Radiotherapy: No prior radiotherapy No concurrent stereotactic boost radiotherapy Surgery: See Disease Characteristics No concurrent surgery for tumor debulking Other: No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete